“Even after India approves the coronavirus vaccine, it might not be possible to produce more than 10-20 million doses in the first year.”The comments came from the Chairperson of Biocon in an exclusive chat with Business Insider.Syngene, a Biocon subsidiary, is involved in accelerating a bunch of initiatives to develop a vaccine for the novel coronavirus that is spreading around the world.There are at least six vaccines under development in India, of the total 100 around the world including from the likes of Sanofi, Altimmune, and Pfizer. “Indian vaccine programmes will take some time before they get into the clinical trials, I think between 6 to 9 months depending on the programme. At least the ones we are working on, I don’t think they can get to clinics before 9 months,” Kiran Mazumdar